Table 3.
Selected ongoing trials in advanced and metastatic cervical cancer.
| Trial Identifier | Study Phase | Treatment Status | Study Population | Intervention |
|---|---|---|---|---|
| ICI + Chemotherapy | ||||
| NCT03635567 | III | Naive | Recurrence/metastatic cervical cancer | Cisplatin/Carboplatin + Paclitaxel + Bevacizumab + Pembrolizumab/placebo |
| NCT03556839 | III | Naive | Stage IVB, persistent/recurrent cervical cancer | Cisplatin/Carboplatin + Paclitaxel + Bevacizumab +/− Atezolizumab |
| NCT03340376 | II | Pre-treated | Recurrent/metastatic cervical cancer | Atezolizumab vs. Doxorubicin vs. Atezolizumab + Doxorubicin |
| NCT03518606 | I/II | Pre-treated | Recurrent/metastatic Cervical, H+N, Breast, Prostate cancer | Durvalumab + Tremelimumab + Vinorelbine |
| NCT04188860 | II | Pre-treated | Recurrent/persistent advanced cervical cancer | Camrelizumab + Nab-paclitaxel |
| ICI + Targeted Therapy | ||||
| NCT03826589 | Pre-treated | Recurrent/metastatic cervical cancer | Avelumab + Axitinib | |
| NCT04357873 | II | Naive/pre-treated | Recurrent/Metastatic SCC (Vulvar, Penile, Cervix, H + N, Anal) | Pembrolizumab + Vorinostat |
| NCT04230954 | II | Naïve (PD-L1 CPS ≥ 1) | Recurrent/Metastatic Cervical cancer | Pembrolizumab + Cabozantinib |
| NCT04483544 | II | ≤2 prior lines | Pembrolizumab + Olaparib | |
| ICI + Radiotherapy | ||||
| NCT03614949 | II | Naive/pre-treated | Recurrent/metastatic Cervical cancer or HPV positive SCC of vagina/vulva. | Atezolizumab + SBRT (24Gy, 3 fractions) |
| NCT03277482 | I | Pre-treated | Recurrent/metastatic gynaecological cancer | Durvalumab, Tremelimumab + Radiation therapy |
| Vaccine Therapy +/− ICI | ||||
| NCT03946358 | II | Pre-treated | Pre-treated locally advanced/metastatic HPV associated cancers | Atezolizumab + UCPVax |
| NCT04405349 | IIa | Pre-treated | HPV16 + ’ve cervical Ca | VB10.16 + Atezolizumab |
| NCT03073525 | II | - | Advanced gynaecological malignancy | Part 2:Vigil x2 → Vigil + Atezolizumab Part 2 comparator: Atezolizumab x2 → Atezolizumab + vigil |
| NCT04432597 | I/II | Naive/pre-treated | Recurrent/metastatic HPV associated cancer | PRGN-2009 +/− M7824 |
| NCT02866006 | I/II | Pre-treated | Recurrent/metastatic HPV 16/18 positive Cervical cancer | BVAC-C |
| NCT02128126 | I/II | Naive | Recurrent/metastatic cervical cancer | ISA101/ISA101b + Carboplatin + paclitaxel +/− Bevacizumab |
| NCT04287868 | I/II | Pre-treated | Advanced HPV associated malignancies | PDS0101 + M7824 + NHS-L12 |
HPV, human papilloma virus; H + N, head and neck; SBRT, stereotactic body radiation therapy.